

WALLSTREETREPORTER®



[Roundtables](#)


[IPO Reporter](#)

[International](#)

[Features](#)

[Analysts](#)

[Leaders](#)



[INTERVIEWS A THRU Z](#)

[ABOUT US](#)

[WSR TELEVISION](#)

[EVENTS](#)

[SUBSCRIBE](#)

[SITE MAP](#)

[HELP AND CONTACT US](#)

[HOME PAGE](#)

WALL STREET REPORTER PRESENTS

ORPHAN THERAPEUTICS PRIVATE


Industry: therapeutics



Interview With:
Peter Teuber, Ph.D.
President
Dated April 25, 2005

[Click here if you don't hear audio](#)

[Download Real Player For Free](#)




CORPORATE INFO

Orphan Therapeutics, LLC is a privately held virtual drug development company. It was founded in 2003 by Peter Teuber, Ph.D. with the purpose of developing specialty products for rare diseases with a high unmet medical need. The business model of Orphan Therapeutics, LLC is to license niche products currently unavailable in the USA, but with proven efficacy for high medical need indications from small European based companies and develop those for FDA approval under Orphan Drug protection. To develop such products efficiently, it is essential to keep the internal infrastructure at a minimum by leveraging strategic partnerships with other experienced independent pharmaceutical executives and organizations (virtual company concept), including the out-licensing of marketing and sales efforts post-approval. The initial focus is on developing and seeking FDA approval of intravenous terlipressin for the treatment of type 1 hepatorenal syndrome (HRS) in the United States. Orphan Therapeutics holds the U.S. investigational new drug application for terlipressin and is conducting a Phase III clinical trial (OT-0401) in the United States and Europe. It has received from the FDA fast track status and the orphan drug designation for terlipressin for the treatment of HRS type 1. PDL's wholly-owned subsidiary, ESP Pharma, Inc., has acquired from Orphan Therapeutics exclusive marketing, sales and distribution rights for terlipressin in the United States and Canada.

[Company Website](#)

IMPORTANT NOTICE AND DISCLAIMER

Wall Street Reporter Weekly News Magazine



Subscribe!!

- TC
- NY
- CAM
- NYSE
- Richa
- CEO
- COR
- PROI
- NYSE
- Rand
- Presi
- Actio
- NYSE
- Fred
- CEO
- Iowa
- Servi
- NYSE
- Mr. A
- Chief
- Agnic
- NYSE
- Sean
- Presi
- NA
- Mobil
- NASI
- Charl
- Chair
- Maje:
- NASI
- Carl
- Chair
- CREI
- NASI
- Charl
- Presi
- PURI
- NASI
- Mark
- Presi
- Nobil
- NASI
- Terry
- Presi
- Chair

CONTENT PARTNERS



Reproduction in part or in whole is strictly forbidden, except by written consent. Linking to Interviews is prohibited without express written permission of the publisher. This is not a solicitation to buy or sell securities. Information in this Article, or Interview contains forward looking statements which involves risks and uncertainties. Actual results can differ from those discussed herein. Information contained here has not been independently verified for completeness, or accuracy and is not meant to offer a complete analysis of the companies financial condition Disclosure in compliance with the Securities and Exchange Commission's 1933 Act Rule 17b: The company has purchased from Wall Street Reporter Magazine, Inc. and or its affiliates, for our financial media program which usually includes the following: re-publication of this interview/article in Wall Street Reporter Magazine, hardcopy reprints of interview, server hosting of audio content, and related graphics/programming services on wallstreetreporter.com, and other media services. If payment has been issued in shares of stock of the Company so retaining the services, Wall Street Reporter Magazine will liquidate said stock when they deem it appropriate to do so. Such liquidation may have a negative impact on the securities of the Company so being sold.

TERMS OF USAGE

Use of this site is covered under the following disclaimer, terms, and conditions. Usage of this site means you, the site visitor, agreed to the following: Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. WallStreetReporter.com does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse, these views, opinions or recommendations, give investment advice, or advocate the purchase or sale of any security or investment. RealAudio Interviews are done without compensation or payment of any kind, by the interviewee / organization. However, companies do pay to have a text version of the interview published online as part of a paid media program. In Compliance with SEC Rule 17B all compensation is disclosed at the bottom of the interview page (in the case of old interviews, by clicking the Important Notice link). Quote or other Data may be delayed as specified by the Exchanges or Sources. WallStreetReporter.com furnishes this information without responsibility for accuracy and it is accepted by the site visitor on the condition that error in transmission or omissions shall not be made the basis for any claim, demand or cause for action against WallStreetReporter.com or any of its Information Providers. WallStreetReporter.com believes its content to be reliable, but accuracy is not warranted or guaranteed. The site visitor agrees not to alter the presentation, reproduce, retransmit, disseminate, sell, distribute, publish, broadcast, circulate or commercially exploit the information in any manner without the express written consent of WallStreetReporter.com; nor to use the Information for any unlawful purpose. WallStreetReporter.com may point to other sites that may of be of interest to the site visitor but for which WallStreetReporter.com has no responsibility and only provides this as a service to the site visitor.

DISCLAIMER

Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. WallStreetReporter.com does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse, these views, opinions or recommendations, give investment advice, or advocate the purchase or sale of any security or investment. RealAudio Interviews are done without compensation or payment of any kind, by the interviewee / organization. However, companies do pay to have a text version of the interview published online as part of a paid media program. In Compliance with SEC Rule 17B all compensation is disclosed at the bottom of the interview page.

IMPORTANT NOTICE

All interviews are copyright-protected intellectual property of Wall Street Reporter Magazine, Inc. Reproduction in whole or in part is strictly forbidden without written permission of the publisher. An express written license is required before linking to any interview or using any of this material in any way for reproduction in print or on another website or media without a license from the Wall Street Reporter Magazine

Wall Street Reporter Magazine, Inc. All Rights Reserved.©1997-2005

Back to Top

FIRS
BAN
NASI
Mr. P
Exec
Chief

Aastr
Nasd
R. Dc
Chair
Chief

AM

MCF
Curh
AME
D. Jo
Chief

Haloz
AME
Jonai
Presi
Chief

FLIG
TECH
AME
Sam
CEO

AXM
AME
Doug
Vice-

BioSi
AME
Stept
Presi
Chief

YAM.
AME.
Peter
Presi

OT

THE
OTCI
Craig
CEO

The f
OTC:
Denn
CEO
York

EARL